To compare the effects of apixaban, warfarin, and no oral anticoagulant (OAC) use among patients with atrial fibrillation (AF) and stage 4 or 5 chronic kidney disease (CKD) who are not undergoing dialysis.
Approach:
Study Design: Cohort study using deidentified data from US health insurance claims resources, comparing initiators of apixaban, warfarin, and non-OAC users.
Eligibility Criteria: Included patients aged 18 or older with CKD stage 4 or 5, AF diagnosis, and specific CHA2DS2-VASc scores, excluding those on dialysis or with certain comorbidities.
Data Analysis: Used multinomial logistic regression for propensity score matching and Cox proportional hazards models for estimating outcomes.
Key Findings:
Oral anticoagulants lower the risk of cardioembolic stroke but increase bleeding risk, particularly in patients with advanced CKD.
Apixaban has FDA approval for use in AF patients with severe kidney impairment.
Existing guidelines on OAC use in advanced CKD vary significantly.
Interpretation:
The study aims to compare the effects of apixaban, warfarin, and no oral anticoagulant use among patients with atrial fibrillation and stage 4 or 5 chronic kidney disease who are not undergoing dialysis.
Limitations:
The study relies on observational data, which may introduce biases.
The generalizability of findings may be limited due to the specific patient population studied.
Conclusion:
The study seeks to provide insights into the safety and efficacy of oral anticoagulants in a high-risk population.
